Suzhou Highfine Biotech Co., Ltd. (SZSE: 301393)
Health Care · Pharmaceuticals · CN
CN¥62.40
-7.05% today · +22.4% 1Y
Suzhou Highfine Biotech Co., Ltd. (SZSE: 301393) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $998.51M.
Over the last twelve months the share price has gained 22.4%, trading between 46.69 and 74.68.
Tweenvest scores Suzhou Highfine Biotech Co., Ltd. across four factors: quality 71/100, value 38/100, growth 62/100, dividend 18/100. Its strongest factor is quality.
301393 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $998.51M
- Revenue (TTM)
- $104.70M
- P/E
- 61.17
- EPS
- 1.02
- Dividend yield
- 0.65%
- Beta (5Y)
- 0.59
- 52-week high
- CN¥74.68
- 52-week low
- CN¥46.69
- Avg volume (3M)
- —
- Shares outstanding
- 107.18M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vetoquinol SAENXTPA: VETO | $1.01B | €75.10 | -3.22% |
| Zhejiang Ausun Pharmaceutical Co., Ltd.SHSE: 603229 | $1.01B | CN¥8.19 | -0.85% |
| Blue Jet Healthcare LimitedNSEI: BLUEJET | $1.01B | Rs514.60 | -5.02% |
| Sunflower Pharmaceutical Group Co., Ltd.SZSE: 002737 | $1.01B | CN¥11.53 | +2.22% |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.SEHK: 1349 | $992.60M | HK$2.55 | +0.59% |
| Cisen Pharmaceutical Co., Ltd.SHSE: 603367 | $992.29M | CN¥14.68 | +1.03% |
| SSY Group LimitedSEHK: 2005 | $981.92M | HK$2.67 | -3.96% |
| Shanghai Haixin Group Co., Ltd.SHSE: 600851 | $979.53M | CN¥7.82 | -1.39% |
Figures last refreshed Oct 11, 2026.